318 related articles for article (PubMed ID: 23108548)
1. Dynamic changes to the endocannabinoid system in models of chronic pain.
Rani Sagar D; Burston JJ; Woodhams SG; Chapman V
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3300-11. PubMed ID: 23108548
[TBL] [Abstract][Full Text] [Related]
2. Why do cannabinoid receptors have more than one endogenous ligand?
Di Marzo V; De Petrocellis L
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3216-28. PubMed ID: 23108541
[TBL] [Abstract][Full Text] [Related]
3. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
[TBL] [Abstract][Full Text] [Related]
4. Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson JL; Bilbrey JA; Felix JS; Makriyannis A; McMahon LR
Pharmacol Biochem Behav; 2021 Jul; 206():173192. PubMed ID: 33932409
[TBL] [Abstract][Full Text] [Related]
5. JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.
Khasabova IA; Yao X; Paz J; Lewandowski CT; Lindberg AE; Coicou L; Burlakova N; Simone DA; Seybold VS
Pharmacol Res; 2014 Dec; 90():67-75. PubMed ID: 25304184
[TBL] [Abstract][Full Text] [Related]
6. Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.
Thomas A; Okine BN; Finn DP; Masocha W
Biomed Pharmacother; 2020 Sep; 129():110456. PubMed ID: 32603895
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis.
Richardson D; Pearson RG; Kurian N; Latif ML; Garle MJ; Barrett DA; Kendall DA; Scammell BE; Reeve AJ; Chapman V
Arthritis Res Ther; 2008; 10(2):R43. PubMed ID: 18416822
[TBL] [Abstract][Full Text] [Related]
8. Opposing roles of CB
Gobira PH; Oliveira AC; Gomes JS; da Silveira VT; Asth L; Bastos JR; Batista EM; Issy AC; Okine BN; de Oliveira AC; Ribeiro FM; Del Bel EA; Aguiar DC; Finn DP; Moreira FA
Br J Pharmacol; 2019 May; 176(10):1541-1551. PubMed ID: 30101419
[TBL] [Abstract][Full Text] [Related]
9. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
10. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow.
Wu J
Acta Pharmacol Sin; 2019 Mar; 40(3):297-299. PubMed ID: 30670816
[No Abstract] [Full Text] [Related]
11. Tonic modulation of spinal hyperexcitability by the endocannabinoid receptor system in a rat model of osteoarthritis pain.
Sagar DR; Staniaszek LE; Okine BN; Woodhams S; Norris LM; Pearson RG; Garle MJ; Alexander SP; Bennett AJ; Barrett DA; Kendall DA; Scammell BE; Chapman V
Arthritis Rheum; 2010 Dec; 62(12):3666-76. PubMed ID: 20722027
[TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target.
Chanda D; Neumann D; Glatz JFC
Prostaglandins Leukot Essent Fatty Acids; 2019 Jan; 140():51-56. PubMed ID: 30553404
[TBL] [Abstract][Full Text] [Related]
13. The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.
Chicca A; Marazzi J; Gertsch J
Br J Pharmacol; 2012 Dec; 167(8):1596-608. PubMed ID: 22646533
[TBL] [Abstract][Full Text] [Related]
14. Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system.
Starowicz K; Przewlocka B
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3286-99. PubMed ID: 23108547
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
16. The Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine.
Ferreira RCM; Castor MGM; Piscitelli F; Di Marzo V; Duarte IDG; Romero TRL
J Pain; 2018 May; 19(5):487-495. PubMed ID: 29247851
[TBL] [Abstract][Full Text] [Related]
17. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
[TBL] [Abstract][Full Text] [Related]
18. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol.
Spoto B; Fezza F; Parlongo G; Battista N; Sgro' E; Gasperi V; Zoccali C; Maccarrone M
Biochimie; 2006 Dec; 88(12):1889-97. PubMed ID: 16949718
[TBL] [Abstract][Full Text] [Related]
19. The cannabinoid system and microglia in health and disease.
Duffy SS; Hayes JP; Fiore NT; Moalem-Taylor G
Neuropharmacology; 2021 Jun; 190():108555. PubMed ID: 33845074
[TBL] [Abstract][Full Text] [Related]
20. Changes in the Brain Endocannabinoid System in Rat Models of Depression.
Smaga I; Jastrzębska J; Zaniewska M; Bystrowska B; Gawliński D; Faron-Górecka A; Broniowska Ż; Miszkiel J; Filip M
Neurotox Res; 2017 Apr; 31(3):421-435. PubMed ID: 28247204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]